2029 Biopharma FDA Patients 
Clarivate
JANUARY 8, 2024
These new treatments hold tremendous promise to advance patient care and fuel the next generation of medical breakthroughs. Clarivate data indicates a 90% probability that datopotamab deruxtecan will win marketing authorization in the United States, and projects 2029 sales of $2.7 billion in 2029 for CASGEVY alone. Granted U.S.
Pharmaceutical Technology
APRIL 4, 2023
of NSCLC patients with exon 19 and 21 mutations develop resistance mutations at C797S. The Boston, Massachusetts-based Scorpion expects to submit an investigational new drug (IND) application for STX-721 to the US Food and Drug Administration (FDA) in mid-2023, with an IND application for STX-241 expected in H1 2024. billion in 2029.
Expert insights. Personalized for you.
59 
Let's personalize your content